# **Special Issue**

# Pharmacovigilance and Appropriate Drug Use

### Message from the Guest Editor

Pharmacovigilance is a key public health process which helps in monitoring the safety of medicines and reducing the risks related to drug use in the post-marketing phase. It works through the detection, assessment, understanding and prevention of adverse effects, or of any medicine-related problems in general.

Nevertheless, the safety of a medicine is related not only to its pharmacological properties, but also to the product's quality and to how it is used in clinical practice. Appropriate drug use helps to avoid medication errors and increase drug safety. Regulatory agencies can use several tools to control and manage each step of the process (from prescription to drug utilization) in order to guarantee the appropriateness of medicine use.

The aim of this Special Issue is to provide an updated panorama of pharmacovigilance issues which resulted (or may result in the future) in regulatory actions and which can be prevented by changing and controlling the prescribing behaviour.

- pharmacovigilance
- safety
- adverse drug reactions
- risk
- regulatory action
- appropriateness

#### **Guest Editor**

Dr. Lucia Gozzo

- 1. Clinical Pharmacology Unit, Regional Pharmacovigilance Centre, University Hospital of Catania, 95123 Catania, Italy
- 2. Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy

### Deadline for manuscript submissions

closed (31 October 2023)



## **Healthcare**

an Open Access Journal by MDPI

Impact Factor 2.7
CiteScore 4.7
Indexed in PubMed



mdpi.com/si/129598

Healthcare
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
healthcare@mdpi.com

mdpi.com/journal/ healthcare





## Healthcare

an Open Access Journal by MDPI

Impact Factor 2.7 CiteScore 4.7 Indexed in PubMed



### **About the Journal**

### Message from the Editor-in-Chief

Healthcare is an international, peerreviewed, open access, multidisciplinary journal. Original research articles, short communications, review articles, and symposium highlights are welcomed.

Healthcare hopes to influence global health and disease aspects, and hopes to gain high visibility and acceptance by the scientific and healthcare community and will dedicate itself to covering special and specific topics in special

We would be pleased to welcome you as one of our authors.

### Editor-in-Chief

issues.

Prof. Dr. Lorraine S. Evangelista

Louise Herrington School of Nursing, Baylor University, Dallas, TX 75246-1754, USA

### **Author Benefits**

### **High Visibility:**

indexed within Scopus, SCIE and SSCI (Web of Science), PubMed, PMC, and other databases.

### **Journal Rank:**

JCR - Q2 (Health Policy and Services) / CiteScore - Q1 (Leadership and Management)

### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).

